Research ArticleOncology
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT
Hossein Jadvar, Erik M. Velez, Bhushan Desai, Lingyun Ji, Patrick M. Colletti and David I. Quinn
Journal of Nuclear Medicine November 2019, 60 (11) 1524-1530; DOI: https://doi.org/10.2967/jnumed.118.223263
Hossein Jadvar
1Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California
Erik M. Velez
1Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California
Bhushan Desai
1Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California
Lingyun Ji
2Department of Preventive Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, California; and
Patrick M. Colletti
1Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California
David I. Quinn
3Division of Cancer Medicine, Department of Medicine, Kenneth J. Norris, Jr., Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, California
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 11
November 1, 2019
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT
Hossein Jadvar, Erik M. Velez, Bhushan Desai, Lingyun Ji, Patrick M. Colletti, David I. Quinn
Journal of Nuclear Medicine Nov 2019, 60 (11) 1524-1530; DOI: 10.2967/jnumed.118.223263
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT
Hossein Jadvar, Erik M. Velez, Bhushan Desai, Lingyun Ji, Patrick M. Colletti, David I. Quinn
Journal of Nuclear Medicine Nov 2019, 60 (11) 1524-1530; DOI: 10.2967/jnumed.118.223263
Jump to section
Related Articles
Cited By...
- A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
- Cut Point Identification of Continuous Biomarkers: A Challenge That Goes Beyond Statistical Aspects
- Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study
- A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration
- Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment